Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function

CHANG-KYU OH, JEONG JUN PARK, MIHYANG HA, HYE JIN HEO, JUNHO KANG, EUN JUNG KWON, JI WAN KANG, YOUNGJOO KIM, JIN MO KANG, SEUNG ZHOO YOON, YEJI KO, DAI SIK KO and YUN HAK KIM
Anticancer Research October 2020, 40 (10) 5601-5609; DOI: https://doi.org/10.21873/anticanres.14573
CHANG-KYU OH
1Center for Genomic Integrity, Institute for Basic Science (IBS), Ulsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEONG JUN PARK
2Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIHYANG HA
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HYE JIN HEO
4Departmment of Anatomy, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNHO KANG
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EUN JUNG KWON
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JI WAN KANG
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOUNGJOO KIM
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JIN MO KANG
5Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEUNG ZHOO YOON
6Department of Anesthesiology and Pain Medicine, Korea University College of Medicine, Anam Hospital, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YEJI KO
7Department of Statistics, University of Michigan, Ann Arbor, MI, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAI SIK KO
5Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daisik.ko@gilhospital.com yunhak10510@pusan.ac.kr
YUN HAK KIM
3Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea
4Departmment of Anatomy, School of Medicine, Pusan National University, Yangsan, Republic of Korea
8Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daisik.ko@gilhospital.com yunhak10510@pusan.ac.kr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Since pathways involving LRRC17 are related to the survival of patients with various cancers, we analyzed LRRC17 as a prognostic gene in serous ovarian cancer. Materials and Methods: Data were collected from Gene Expression Omnibus (GSE9891, GSE13876, and GSE26712) and The Cancer Genome Atlas (TCGA). We performed survival analyses using C statistics, area under the curve, survival plot with optimal cutoff level, and cox proportional regression. Zebrafish embryos were used as an in vivo model. Results: The prognosis of patients with high LRRC17 expression was poorer than that of patients with low LRRC17 expression. Multivariate regression analysis showed that LRRC17 expression, age, and stage were independently related with survival. Knockdown of lrrc17 reduced survival rate and delayed development in zebrafish embryos. We also found that lrrc17 is important for cell viability by protecting from p53-dependent apoptosis. Conclusion: LRRC17 could be a prognostic gene in ovarian cancer as it regulates cancer cell viability through the p53 pathway.

  • Ovarian epithelial cancer
  • LRRC17
  • survival analysis
  • zebrafish
  • apoptosis
  • gene expression omnibus
  • TCGA

Ovarian tumor is the most severe type of tumor among gynecologic cancers in the United States (1). Around 22,200 patients were diagnosed with ovarian cancer and about 14,000 women died due to ovarian cancer in 2018 in the Unites States (2). In 90% of ovarian cancer patients, the tumor has an epithelial origin, and is classified in 5 histological types, namely, serous, clear cell, endometrioid, mucinous, and undifferentiated. Serous ovarian carcinoma (SOC) constitutes about 70% of epithelial ovarian cancers (3). Since SOCs are usually diagnosed at stage III or IV (51% or 29%), the 5-year disease specific survival of SOC patients is 43%. However, 5-year disease specific survival of other histological types (endometrioid, mucinous, and clear cell carcinoma) of ovarian cancer are 82%, 71%, and 66%, respectively (2).

The 5-year survival of SOC patients varies significantly with the stage of cancer, ranging from 92% for early stage cancer to 27% for late stage cancer (4). Even though significant progresses have been made in both surgical and pharmaceutical treatment strategies, survival rates remain poor (5). One of the major factors associated with poor outcomes of ovarian cancer include the lack of clinically relevant and accurate prognostic biomarkers. Yet, cancer stage, histologic type, tumor grade, debulking status, and cancer antigen 125 (CA-125) constitute the current mainstay for predicting prognosis of SOC (6).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics in GSE9891, GSE13876, GSE26712, TCGA, GSE6008, and GSE27651 cohorts.

Leucine-rich-containing 17 (LRRC17), a secreted protein containing five Leucine-rich-containing domains, has been identified by cDNA subtraction experiments in the S-type neuroblastoma cell line (7). LRRC17 is an inhibitor of receptor activator of NF-ĸB ligand (RANKL)-induced osteoclastogenesis (8). Decreased LRRC17 has been shown to be a serum risk marker for osteoporotic fracture in the spines of postmenopausal women (9). Besides bone metabolism, Christopher et al. have reported that the expression of LRRC17 is particularly high in both oocyte and granulosa cells of follicles (10). Although LRRC17 is highly expressed in female tissues according to Human Protein Atlas, correlation between LRRC17 and ovarian cancer is still unveiled.

In this study, to develop and verify the LRRC17 gene as a potential prognostic and diagnostic factor for SOC, four large scale cohorts [GSE9891, GSE13876, GSE26712 from the Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA)] were analyzed. In addition, we investigated the role of lrrc17 in zebrafish.

Materials and Methods

Patient data. Data from four cohorts were obtained from GEO (11) and TCGA (12) in March 2019 (13-18). Patients with insufficient clinical and/or genomic information were excluded as described before (19, 20). The characteristics of the patients in each cohort are presented in Table I.

Zebrafish maintenance and MO injection. Adult wild-type AB zebrafish were maintained in an automatic circulation system (Genomic-Design) at 28.5°C. All experiments with zebrafish were performed in accordance with the guidelines of Ulsan National Institute of Science and Technology (UNIST) Institutional Animal Care and Use Committee (IACUC) (IACUC approval number: UNISTIACUC-15-15) and ARRIVE/NC3R. Zebrafish embryos were maintained with E3 solution in incubators at 28°C. A translation-blocking morpholino targeting lrrc17 (Gene Tools, Philomath, OR, USA) was dissolved in DEPC-treated water at the stock concentration of 25 ng/nl. The sequence of lrrc17-MO is 5’-AGCCGCATGGCAAAAAGCAGCAGCT-3’. Thirty embryos were injected with 1.0, 2.5 and 5.0 ng of morpholino at the 1 or 2 cell stage of development for each experimental group. All experiments were performed in three biological replicates for validation. Survival rate of embryos was compared between groups by t-test. Microinjections were performed with a Femtojet 4i microinjector (Eppendorf, Hamburg, Germany).

Acridine orange (AO) stain using zebrafish embryos. Embryos were incubated with 50 μg/ml of Acridine orange solution (Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 28°C in the dark. After staining, embryos were washed three times with E3 buffer. Then, zebrafish embryos were anesthetized using tricaine and observed using confocal microscope (LSM880, Carl Zeiss, Oberkochen, Germany).

Whole-mount in situ hybridization (WISH). For fixation, embryos were anesthetized with 76 mM of tricaine, and sacrificed with 0.76 M of tricaine. Then, embryos were fixed using 4% paraformaldehyde in PBS, and dehydrated with methanol at −20°C overnight. Samples were incubated with cold acetone at −20°C for permeabilization. Then, samples were hybridized with a digoxigenin (DIG)-labeled antisense RNA probe in hybridization buffer (50% formamide, SSC solution (0.75 M sodium chloride, 0.075 M trisodium citrate), 500 μg/ml Torula yeast tRNA, 50 μg/ml heparin, 0.1% Tween-20, and 9 mM citric acid (pH 6.5) for 3 days. The samples were washed with diluted SSC solution (30 mM sodium chloride, 3 mM trisodium citrate). Washed samples were blocked with normal goat serum and bovine serum albumin, and incubated with alkaline phosphate-conjugated DIG antibodies (1:5,000) (Roche, Mannheim, Germany) overnight at 4°C. Samples were incubated with the alkaline phosphatase reaction buffer [100 mM Tris (pH 9.5), 50 mM MgCl2, 100 mM NaCl, and 0.1% Tween-20] and the NBT/BCIP substrate (Promega, Madison, WI, USA) for visualization of the signal.

Statistical methods. We performed survival analyses to predict prognosis as described previously (21-23). To discriminate the risk of patients, we performed several survival analyses using Uno's C statistics in the time-dependent area under the curve (AUC), AUCs in the receiver operating characteristic (ROC) curve at 3 years, a survival plot with optimal cutoff, and cox proportional regression. The LRRC17 cutoff level in this study was the maximal Uno's C-index in each dataset. In survival analyses, we evaluated the prognostic significances of LRRC17 as a categorical value. We used Wilcoxon signed rank sum test to identify the expression differences of LRRC17 between healthy individuals and cancer patients. All statistical methods were performed using R software 3.5.1 (The R foundation for Statistical Computing, 2018).

Results

Patient information. We collected the information regarding the characteristics of all patients from four cohorts (GSE9891, n=242; GSE13876, n=157; GSE26712, n=185; TCGA, n=306) (Table I). Two cohorts had information regarding the patients' stage of SOC.

Evaluating the prognostic significance of LRRC17. To assess whether LRRC17 is a prognostic biomarker for SOC, we performed Kaplan–Meier analysis to estimate the relationship between the expression values of LRRC17 and patient survival. Optimal cutoff values of LRRC17 in GSE9891, GSE13876, GSE26712, and TCGA were 4.356, 548.058, 5.870, and 53.908, respectively. LRRC17 was notably related to prognosis of patients in all cohorts (Figure 1). The overall survival of SOC patients with high LRRC17 expression was lower than that of patients with low LRRC17 expression; TCGA (p=0.0022), GSE9891 (p=0.00088), GSE13876 (p=0.013), and GSE26712 (p<0.0001) (Figure 1A-D). To evaluate the prognostic significance of LRRC17 expression in SOC, we used Uno's C-index and the AUCs (Figure 1E-F). The C-indexes in the time-dependent curve were 0.593, 0.602, 0.619, and 0.578 for TCGA, GSE9891, GSE13876, and GSE26712, respectively (Figure 1E). In the 3-year ROC curves, the AUC values for TCGA, GSE9891, GSE13876, and GSE26712 were 0.643, 0.592, 0.629, and 0.546, respectively (Figure 1F).

To examine whether LRRC17 expression value is a self-sufficient prognostic factor for SOC, we used uni- and multi-variate COX proportional regressions. In univariate COX regression, LRRC17 expression (p=0.001), age (p=0.046) and stage (p=0.014) were related to overall survival in GSE9891, while LRRC17 expression was related to survival in GSE13876 (p=0.013) and GSE26712 (p≤0.001); LRRC17 expression (p=0.002) and age (p<0.001) were related to overall survival in TCGA (Table II). After adjustment for the significant parameter, multivariate regression analyses showed that LRRC17 expression (p<0.001), age (p=0.044), and stage (p=0.029) were independently related to overall survival in GSE9891; LRRC17 expression (p=0.011) in GSE13876; and LRRC17 expression (p=0.011) in TCGA (Table II).

LRRC17 expression as a marker for advancement of cancer stage. To determine whether changes in the expression indicate advancement of cancer stage, we compared the expression of LRRC17 between early stages (I & II) and advanced stages (III & IV) of cancer from TCGA and GSE9891. In both cohorts, the expression of LRRC17 was higher at early stages compared to that of advanced stages (Figure 2).

LRRC17 is evolutionally conserved in vertebrates. Although LRRC17 is known to be a negative regulator of the RANKL pathway, this cannot explain the correlation between LRRC17 expression and prognosis of SOC patients. To investigate the novel function of LRRC17, we used zebrafish embryos as an in vivo model. We compared the amino acid sequence of human LRRC17 and zebrafish paralog, lrrc17. Using Pubmed protein blast, we confirmed that 53% of amino acids residues were exactly the same, and 15% of the other amino acid residues had similar structure. This indicates that LRRC17 is evolutionally conserved in vertebrates and may have other functions in addition to bone differentiation.

Zebrafish paralog, lrrc17 promotes cell viability by protecting from p53-dependent apoptosis. Since lrrc17 has only one exon, we used translation blocking morpholino instead of splicing-blocking morpholino. To optimize the dosage of morpholino, we injected 1, 2.5 and 5 ng of translation blocking morpholino to 30 zebrafish embryos in biological triplicates. As the concentration of morpholino increased, the development of embryos delayed (Figure 3A). Then, the survival rate was compared between uninjected embryos and morpholino-injected embryos by t-test. The survival rate of embryos was reduced following injection with 5 ng morpholino compared to uninjected embryos (Figure 3B). These results suggest that lrrc17 is linked to viability in addition to bone differentiation.

While LRRC17 is known to be a negative regulator of the RANKL pathway (8), another LRR family protein, LRRN1, is known as a negative regulator of apoptosis through the regulation of Fas/FasL (24). Therefore, we examined the hypothesis that, similar to LRRN1, lrrc17 could be related to apoptosis, by using AO staining of lrrc17-morphants. Injection with 2.5 ng and 5 ng of morpholino delayed the development of embryos (Figure 3A). These concentrations were considered high and that they may have off-target effects. To avoid off-target effects of morpholino, we used 1 ng of morpholino for AO staining.

Compared to uninjected control embryos, lrrc17-morphants show a high number of AO-positive cells in embryos (Figure 4A). Since p53 is the most common and important key molecule in apoptosis (25), expression of p53 was examined using WISH in lrrc17-morphants. As the signal of AO was increased in lrrc17-morphants, the signal of p53 was also increased (Figure 4B). These results suggest that lrrc17 supports cell viability by protecting from p53-dependent apoptosis.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Survival analysis of patients with SOC. (A-D) Kaplan–Meier survival analysis of patients with SOC with respect to LRRC17 gene expression. Survival analysis was performed in patients with SOC from GSE9891 (A), GSE13876 (B), GSE26712 (C), and TCGA (D). The p-value was calculated using log-rank test and is provided at the bottom left corner of each dataset. (E-F) Time-dependent area under the curve (AUC) analysis and receiver operating characteristic (ROC) curves at 5 years with respect to LRRC17 gene expression. Time-dependent AUC (E) and ROC curve at 3 years (F) in the GSE9891, GSE13876, GSE26712, and TCGA. C-index values and AUC values at 3 years are provided at the bottom right corner of each cohort.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate and multivariate analysis of overall survival in each cohort.

Discussion

In this study, by analyzing large-scale cohorts (GSE9891, GSE13876, GSE26712, and TCGA), we found that LRRC17 is a potent prognostic factor in SOC as much as cancer stage in the FIGO system. In addition to bone differentiation, we found that lrrc17 plays an important role in cell viability by protecting from p53-dependent apoptosis in zebrafish embryos.

The cancer antigen 125 (CA 125) was used to screen and monitor ovarian cancer as a serum marker. Since the efficacy of CA 125 as a biomarker is low, major efforts have been made to enhance the performance of CA 125 by combining it with ultrasonography in several studies (26-29). However, the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial has not shown mortality benefit (27). In the United Kingdom Collaborative Trial of Ovarian Cancer Screening, multimodal screening resulted in significantly increased detection of early stage invasive epithelial ovarian/tubal/peritoneal cancers compared to the control arm (29). They also showed a mortality benefit; however, further follow-up is needed to assess whether screening results in a definitive mortality reduction. Human epididymis protein 4 (HE4) has been investigated as a biomarker for ovarian cancer. HE4 has higher expression in the patients with ovarian cancer compared to healthy persons (30). Furthermore, several studies have examined whether the combination of HE4 with CA 125 is a biological marker (31, 32). However, several factors influence serum HE4 concentration, such as age, smoking, kidney function, and non-gynecologic malignancies (33).

With the compelling need to identify new biomarkers for personalized and predictive medicine, several molecular profiling studies have recently been performed. In the CLOVAR study, using the TCGA dataset, four distinct prognostically relevant subtypes were revealed (34). Due to advances in bioinformatics, through analyzing multiple expression profiles from GEO, Esra et al. have developed a co-regulated gene module in ovarian cancer consisting of 84 prognostic genes (35) and Chuan-Di et al. screened out 11 genes associated with prognosis of ovarian cancer (36). These transcriptomic studies provide insights for research towards the identification of biomarkers, yet the molecular pathways in modules consisting of gene clusters need to be validated experimentally. In addition to transcriptomic biomarkers, miRNAs have been widely studied. The role of miR-200 family as a prognostic biomarker in ovarian cancer has been reported by multiple studies (37, 38). Because of inconsistencies in miRNA-based biomarkers, they have not yet been brought to clinical practice (39).

In our study, high expression of LRRC17 in all patients with SOC from all cohorts was correlated with poor overall survival. The p value regarding the expression of LRRC17 in multivariate analysis in the GSE9891 cohort was lower than that in univariate analysis (from p=0.001 to p<0.001), while the p-value regarding stage was higher than that in univariate analysis (from p=0.014 to p=0.029). Moreover, in the TCGA dataset, cancer stage was not a risk factor for overall survival in univariate analysis. This implies that LRRC17 is a more potent prognostic factor than stage regarding the overall survival of patients with SOC. These results suggest that LRRC17 could be applicable as a diagnostic and prognostic biomarker for SOC.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Comparison of LRRC17 gene expression between stage I, II, III and IV from TCGA (A) and GSE9891 (B).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Zebrafish paralog, lrrc17 is important for the development and survival of embryos. (A) Representative images of uninjected embryos and lrrc17-morpholino injected embryos (1.0 ng, 2.5 ng, and 5.0 ng) at 24 h post fertilisation (hpf). Black arrows indicate delayed development of zebrafish embryos. (B) Survival rate of uninjected zebrafish embryos and lrrc17-morpholino injected embryos (1.0 ng, 2.5 ng, and 5.0 ng) at 24 hpf. Survival rate is measured using 30 embryos with three biological replicates.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

lrrc17 is important for cell viability by protecting from p53-dependent apoptosis. (A) Lateral view of confocal imaging after AO staining using uninjected embryos and 1 ng of lrrc17-morpholino injected embryos at 26 24 h post fertilisation (hpf). Representative images selected from 30 uninjected embryos and lrrc17-morpholino injected embryos. (B) Lateral view of whole-mount in situ hybridization imaging using a probe for p53. Thirty embryos were fixed 26 hpf. All results are representative images from three biological replicates.

This is the first study to evaluate LRRC17 as a prognostic marker for SOC. By analyzing large-scale publicly accessible four cohorts, we gained high statistical power. Additionally, we found that lrrc17 in zebrafish embryos is important for cell viability by protecting from apoptosis. As LRRN1 is linked to negative regulation of apoptosis through Fas/FasL (24), lrrc17 was also found to be a negative regulator of p53-dependent apoptosis. In a previous study, we have shown that the basal levels of p53 are important for drug resistance in colon cancer (40). This means that high levels of LRRC17 can inhibit chemotherapy-induced apoptosis in SOC. However, for clinical application, identification of a more specific mechanism of LRRC17 function is necessary. In conclusion, LRRC17 could be applicable as a prognostic gene in addition to cancer stage.

Acknowledgements

This study was supported by Gachon University Gil Medical Center (FRD2019-09) and grants from the Medical Research Center (MRC) Program through the National Research Foundation of Korea (NRF) funded by the Korea government (NRF-2018R1A5A2023879). This work was supported by the Institute for Basic Science (IBS-R022-D1).

Footnotes

  • ↵* These Authors contributed equally to this work.

  • Authors' Contributions

    DSK and YHK made substantial contributions to the conception and design. HJH, JK, and EJK collected data and JWK, YK (Yoongjoo Kim), and YK (Yeji Ko) performed statistical analysis. JJP and MH analyzed and interpreted the data. CO produced data using zebrafish. DSK and CO wrote the manuscript. JMK, KH, and SZY made critical revision.

  • Conflicts of Interest

    All Authors have declared that they have no conflicts of interest to disclose in relation to this study.

  • Received August 7, 2020.
  • Revision received August 24, 2020.
  • Accepted August 25, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Jemal A,
    2. Siegel R,
    3. Ward E,
    4. Murray T,
    5. Xu J,
    6. Thun MJ
    : Cancer statistics, 2007. CA Cancer J Clin 57(1): 43-66, 2007. PMID: 17237035, DOI: 10.3322/canjclin.57.1.43
    OpenUrlCrossRefPubMed
  2. ↵
    1. Torre LA,
    2. Trabert B,
    3. DeSantis CE,
    4. Miller KD,
    5. Samimi G,
    6. Runowicz CD,
    7. Gaudet MM,
    8. Jemal A,
    9. Siegel RL
    : Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4): 284-296, 2018. PMID: 29809280. DOI: 10.3322/caac.21456
    OpenUrlCrossRefPubMed
  3. ↵
    1. Prat J
    : New insights into ovarian cancer pathology. Ann Oncol 23: x111-117, 2012. PMID: 22987944. DOI: 10.1093/annonc/mds300
    OpenUrlCrossRefPubMed
  4. ↵
    1. Jayson GC,
    2. Kohn EC,
    3. Kitchener HC,
    4. Ledermann JA
    : Ovarian cancer. Lancet 384(9951): 1376-1388, 2014. PMID: 24767708. DOI: 10.1016/s0140-6736(13)62146-7
    OpenUrlCrossRefPubMed
  5. ↵
    1. McDaniel AS,
    2. Stall JN,
    3. Hovelson DH,
    4. Cani AK,
    5. Liu CJ,
    6. Tomlins SA,
    7. Cho KR
    : Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol 1(8): 1128-1132, 2015. PMID: 26181193. DOI: 10.1001/jamaoncol.2015.1618
    OpenUrl
  6. ↵
    1. Gupta S,
    2. Nag S,
    3. Aggarwal S,
    4. Rauthan A,
    5. Warrier N
    : Maintenance therapy for recurrent epithelial ovarian cancer: Current therapies and future perspectives - a review. J Ovarian Res 12(1): 103, 2019. PMID: 31685032. DOI: 10.1186/s13048-019-0579-0
    OpenUrl
  7. ↵
    1. Kim D,
    2. LaQuaglia MP,
    3. Yang SY
    : A cdna encoding a putative 37 kda leucine-rich repeat (lrr) protein, p37nb, isolated from s-type neuroblastoma cell has a differential tissue distribution. Biochim Biophys Acta 1309(3): 183-188, 1996. PMID: 8982252. DOI: 10.1016/s0167-4781(96)00158-3
    OpenUrlPubMed
  8. ↵
    1. Kim T,
    2. Kim K,
    3. Lee SH,
    4. So HS,
    5. Lee J,
    6. Kim N,
    7. Choi Y
    : Identification of lrrc17 as a negative regulator of receptor activator of nf-kappab ligand (rankl)-induced osteoclast differentiation. J Biol Chem 284(22): 15308-15316, 2009. PMID: 19336404. DOI: 10.1074/jbc.M807722200
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hong N,
    2. Kim BJ,
    3. Kim CH,
    4. Baek KH,
    5. Min YK,
    6. Kim DY,
    7. Lee SH,
    8. Koh JM,
    9. Kang MI,
    10. Rhee Y
    : Low plasma level of leucine-rich repeat-containing 17 (lrrc17) is an independent and additive risk factor for osteoporotic fractures in postmenopausal women. J Bone Miner Res 31(12): 2106-2114, 2016. PMID: 27355564. DOI: 10.1002/jbmr.2902
    OpenUrl
  10. ↵
    1. Malcuit C,
    2. Trask MC,
    3. Santiago L,
    4. Beaudoin E,
    5. Tremblay KD,
    6. Mager J
    : Identification of novel oocyte and granulosa cell markers. Gene Expr Patterns 9(6): 404-410, 2009. PMID: 19539053. DOI: 10.1016/j.gep.2009.06.004
    OpenUrlPubMed
  11. ↵
    1. National Center for Biotechnology Information
    . Gene Expression Omnibus. Available at: https://www.ncbi.nlm.nih.gov [Last accessed March 30, 2019]
  12. ↵
    1. National Cancer Institute
    . The Cancer Genome Atlas. Available at: https://portal.gdc.cancer.gov [Last accessed March 30, 2019]
  13. ↵
    1. Bonome T,
    2. Levine DA,
    3. Shih J,
    4. Randonovich M,
    5. Pise-Masison CA,
    6. Bogomolniy F,
    7. Ozbun L,
    8. Brady J,
    9. Barrett JC,
    10. Boyd J,
    11. Birrer MJ
    : A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68(13): 5478-5486, 2008. PMID: 18593951. DOI: 10.1158/0008-5472.Can-07-6595
    OpenUrlAbstract/FREE Full Text
    1. Tothill RW,
    2. Tinker AV,
    3. George J,
    4. Brown R,
    5. Fox SB,
    6. Lade S,
    7. Johnson DS,
    8. Trivett MK,
    9. Etemadmoghadam D,
    10. Locandro B,
    11. Traficante N,
    12. Fereday S,
    13. Hung JA,
    14. Chiew YE,
    15. Haviv I,
    16. Gertig D,
    17. DeFazio A,
    18. Bowtell DD
    : Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16): 5198-5208, 2008. PMID: 18698038. DOI: 10.1158/1078-0432.Ccr-08-0196
    OpenUrlAbstract/FREE Full Text
    1. Crijns AP,
    2. Fehrmann RS,
    3. de Jong S,
    4. Gerbens F,
    5. Meersma GJ,
    6. Klip HG,
    7. Hollema H,
    8. Hofstra RM,
    9. te Meerman GJ,
    10. de Vries EG,
    11. van der Zee AG
    : Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6(2): e24, 2009. PMID: 19192944. DOI: 10.1371/journal.pmed.1000024
    OpenUrlCrossRefPubMed
    1. Cerami E,
    2. Gao J,
    3. Dogrusoz U,
    4. Gross BE,
    5. Sumer SO,
    6. Aksoy BA,
    7. Jacobsen A,
    8. Byrne CJ,
    9. Heuer ML,
    10. Larsson E,
    11. Antipin Y,
    12. Reva B,
    13. Goldberg AP,
    14. Sander C,
    15. Schultz N
    : The cbio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5): 401-404, 2012. PMID: 22588877. DOI: 10.1158/2159-8290.Cd-12-0095
    OpenUrlAbstract/FREE Full Text
    1. Gonzalez-Perez A,
    2. Perez-Llamas C,
    3. Deu-Pons J,
    4. Tamborero D,
    5. Schroeder MP,
    6. Jene-Sanz A,
    7. Santos A,
    8. Lopez-Bigas N
    : Intogen-mutations identifies cancer drivers across tumor types. Nat Methods 10(11): 1081-1082, 2013. PMID: 24037244. DOI: 10.1038/nmeth.2642
    OpenUrlCrossRefPubMed
  14. ↵
    1. Vathipadiekal V,
    2. Wang V,
    3. Wei W,
    4. Waldron L,
    5. Drapkin R,
    6. Gillette M,
    7. Skates S,
    8. Birrer M
    : Creation of a human secretome: A novel composite library of human secreted proteins: Validation using ovarian cancer gene expression data and a virtual secretome array. Clin Cancer Res 21(21): 4960-4969, 2015. PMID: 25944803. DOI: 10.1158/1078-0432.Ccr-14-3173
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Ha M,
    2. Jeong H,
    3. Roh JS,
    4. Lee B,
    5. Han ME,
    6. Oh SO,
    7. Sohn DH,
    8. Kim YH
    : Dysf expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts. Urol Oncol 37(10): 735-741, 2019. PMID: 31377166. DOI: 10.1016/j.urolonc.2019.07.007
    OpenUrl
  16. ↵
    1. Ha M,
    2. Moon H,
    3. Choi D,
    4. Kang W,
    5. Kim JH,
    6. Lee KJ,
    7. Park D,
    8. Kang CD,
    9. Oh SO,
    10. Han ME,
    11. Kim YH,
    12. Lee D
    : Prognostic role of tmed3 in clear cell renal cell carcinoma: A retrospective multi-cohort analysis. Front Genet 10: 355, 2019. PMID: 31057605. DOI: 10.3389/fgene.2019.00355
    OpenUrl
  17. ↵
    1. Goh TS,
    2. Ha M,
    3. Lee JS,
    4. Jeong DC,
    5. Jung ES,
    6. Han ME,
    7. Kim YH,
    8. Oh SO
    : Prognostic significance of eif4g1 in patients with pancreatic ductal adenocarcinoma. Onco Targets Ther 12: 2853-2859, 2019. PMID: 31043796. DOI: 10.2147/ott.S202101
    OpenUrl
    1. Han ME,
    2. Kim JY,
    3. Kim GH,
    4. Park SY,
    5. Kim YH,
    6. Oh SO
    : Sac3d1: A novel prognostic marker in hepatocellular carcinoma. Sci Rep 8(1): 15608, 2018. PMID: 30353105. DOI: 10.1038/s41598-018-34129-9
    OpenUrlCrossRef
  18. ↵
    1. Pak K,
    2. Oh SO,
    3. Goh TS,
    4. Heo HJ,
    5. Han ME,
    6. Jeong DC,
    7. Lee CS,
    8. Sun H,
    9. Kang J,
    10. Choi S,
    11. Lee S,
    12. Kwon EJ,
    13. Kang JW,
    14. Kim YH
    : A user-friendly, web-based integrative tool (esurv) for survival analysis: Development and validation study. J Med Internet Res 22(5): e16084, 2020. PMID: 32369034. DOI: 10.2196/16084
    OpenUrl
  19. ↵
    1. Liu B,
    2. Zhang Y,
    3. Fan Y,
    4. Wang S,
    5. Li Z,
    6. Deng M,
    7. Li C,
    8. Wang J,
    9. Ma R,
    10. Wang X,
    11. Wang Y,
    12. Xu L,
    13. Hou K,
    14. Che X,
    15. Liu Y,
    16. Qu X
    : Leucine-rich repeat neuronal protein-1 suppresses apoptosis of gastric cancer cells through regulation of fas/fasl. Cancer Sci 110(7): 2145-2155, 2019. PMID: 31087525. DOI: 10.1111/cas.14042
    OpenUrl
  20. ↵
    1. Aubrey BJ,
    2. Kelly GL,
    3. Janic A,
    4. Herold MJ,
    5. Strasser A
    : How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25(1): 104-113, 2018. PMID: 29149101. DOI: 10.1038/cdd.2017.169
    OpenUrlCrossRef
  21. ↵
    1. Kobayashi H,
    2. Yamada Y,
    3. Sado T,
    4. Sakata M,
    5. Yoshida S,
    6. Kawaguchi R,
    7. Kanayama S,
    8. Shigetomi H,
    9. Haruta S,
    10. Tsuji Y,
    11. Ueda S,
    12. Kitanaka T
    : A randomized study of screening for ovarian cancer: A multicenter study in japan. Int J Gynecol Cancer 18(3): 414-420, 2008. PMID: 17645503. DOI: 10.1111/j.1525-1438.2007.01035.x
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Buys SS,
    2. Partridge E,
    3. Black A,
    4. Johnson CC,
    5. Lamerato L,
    6. Isaacs C,
    7. Reding DJ,
    8. Greenlee RT,
    9. Yokochi LA,
    10. Kessel B,
    11. Crawford ED,
    12. Church TR,
    13. Andriole GL,
    14. Weissfeld JL,
    15. Fouad MN,
    16. Chia D,
    17. O'Brien B,
    18. Ragard LR,
    19. Clapp JD,
    20. Rathmell JM,
    21. Riley TL,
    22. Hartge P,
    23. Pinsky PF,
    24. Zhu CS,
    25. Izmirlian G,
    26. Kramer BS,
    27. Miller AB,
    28. Xu JL,
    29. Prorok PC,
    30. Gohagan JK,
    31. Berg CD
    : Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial. JAMA 305(22): 2295-2303, 2011. PMID: 21642681. DOI: 10.1001/jama.2011.766
    OpenUrlCrossRefPubMed
    1. van Nagell JR Jr..,
    2. Miller RW,
    3. DeSimone CP,
    4. Ueland FR,
    5. Podzielinski I,
    6. Goodrich ST,
    7. Elder JW,
    8. Huang B,
    9. Kryscio RJ,
    10. Pavlik EJ
    : Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 118(6): 1212-1221, 2011. PMID: 22105249. DOI: 10.1097/AOG.0b013e318238d030
    OpenUrlCrossRefPubMed
  23. ↵
    1. Jacobs IJ,
    2. Menon U,
    3. Ryan A,
    4. Gentry-Maharaj A,
    5. Burnell M,
    6. Kalsi JK,
    7. Amso NN,
    8. Apostolidou S,
    9. Benjamin E,
    10. Cruickshank D,
    11. Crump DN,
    12. Davies SK,
    13. Dawnay A,
    14. Dobbs S,
    15. Fletcher G,
    16. Ford J,
    17. Godfrey K,
    18. Gunu R,
    19. Habib M,
    20. Hallett R,
    21. Herod J,
    22. Jenkins H,
    23. Karpinskyj C,
    24. Leeson S,
    25. Lewis SJ,
    26. Liston WR,
    27. Lopes A,
    28. Mould T,
    29. Murdoch J,
    30. Oram D,
    31. Rabideau DJ,
    32. Reynolds K,
    33. Scott I,
    34. Seif MW,
    35. Sharma A,
    36. Singh N,
    37. Taylor J,
    38. Warburton F,
    39. Widschwendter M,
    40. Williamson K,
    41. Woolas R,
    42. Fallowfield L,
    43. McGuire AJ,
    44. Campbell S,
    45. Parmar M,
    46. Skates SJ
    : Ovarian cancer screening and mortality in the uk collaborative trial of ovarian cancer screening (ukctocs): A randomised controlled trial. Lancet 387(10022): 945-956, 2016. PMID: 26707054. DOI: 10.1016/s0140-6736(15)01224-6
    OpenUrlCrossRefPubMed
  24. ↵
    1. Drapkin R,
    2. von Horsten HH,
    3. Lin Y,
    4. Mok SC,
    5. Crum CP,
    6. Welch WR,
    7. Hecht JL
    : Human epididymis protein 4 (he4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6): 2162-2169, 2005. PMID: 15781627. DOI: 10.1158/0008-5472.Can-04-3924
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Van Gorp T,
    2. Cadron I,
    3. Despierre E,
    4. Daemen A,
    5. Leunen K,
    6. Amant F,
    7. Timmerman D,
    8. De Moor B,
    9. Vergote I
    : He4 and ca125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer 104(5): 863-870, 2011. PMID: 21304524. DOI: 10.1038/sj.bjc.6606092
    OpenUrlCrossRefPubMed
  26. ↵
    1. Zhang L,
    2. Chen Y,
    3. Wang K
    : Comparison of ca125, he4, and roma index for ovarian cancer diagnosis. Curr Probl Cancer 43(2): 135-144, 2019. PMID: 30017407. DOI: 10.1016/j.currproblcancer.2018.06.001
    OpenUrl
  27. ↵
    1. Ferraro S,
    2. Schiumarini D,
    3. Panteghini M
    : Human epididymis protein 4: Factors of variation. Clin Chim Acta 438: 171-177, 2015. PMID: 25172040. DOI: 10.1016/j.cca.2014.08.020
    OpenUrlCrossRef
  28. ↵
    1. Verhaak RG,
    2. Tamayo P,
    3. Yang JY,
    4. Hubbard D,
    5. Zhang H,
    6. Creighton CJ,
    7. Fereday S,
    8. Lawrence M,
    9. Carter SL,
    10. Mermel CH,
    11. Kostic AD,
    12. Etemadmoghadam D,
    13. Saksena G,
    14. Cibulskis K,
    15. Duraisamy S,
    16. Levanon K,
    17. Sougnez C,
    18. Tsherniak A,
    19. Gomez S,
    20. Onofrio R,
    21. Gabriel S,
    22. Chin L,
    23. Zhang N,
    24. Spellman PT,
    25. Zhang Y,
    26. Akbani R,
    27. Hoadley KA,
    28. Kahn A,
    29. Köbel M,
    30. Huntsman D,
    31. Soslow RA,
    32. Defazio A,
    33. Birrer MJ,
    34. Gray JW,
    35. Weinstein JN,
    36. Bowtell DD,
    37. Drapkin R,
    38. Mesirov JP,
    39. Getz G,
    40. Levine DA,
    41. Meyerson M
    : Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123(1): 517-525, 2013. PMID: 23257362. DOI: 10.1172/jci65833
    OpenUrlCrossRefPubMed
  29. ↵
    1. Gov E,
    2. Arga KY
    : Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer. Sci Rep 7(1): 4996, 2017. PMID: 28694494. DOI: 10.1038/s41598-017-05298-w
    OpenUrl
  30. ↵
    1. Men CD,
    2. Liu QN,
    3. Ren Q
    : A prognostic 11 genes expression model for ovarian cancer. J Cell Biochem 119(2): 1971-1978, 2018. PMID: 28817186. DOI: 10.1002/jcb.2635
    OpenUrl
  31. ↵
    1. Marchini S,
    2. Cavalieri D,
    3. Fruscio R,
    4. Calura E,
    5. Garavaglia D,
    6. Fuso Nerini I,
    7. Mangioni C,
    8. Cattoretti G,
    9. Clivio L,
    10. Beltrame L,
    11. Katsaros D,
    12. Scarampi L,
    13. Menato G,
    14. Perego P,
    15. Chiorino G,
    16. Buda A,
    17. Romualdi C,
    18. D'Incalci M
    : Association between mir-200c and the survival of patients with stage i epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 12(3): 273-285, 2011. PMID: 21345725. DOI: 10.1016/s1470-2045(11)70012-2
    OpenUrlCrossRefPubMed
  32. ↵
    1. Deb B,
    2. Uddin A,
    3. Chakraborty S
    : Mirnas and ovarian cancer: An overview. J Cell Physiol 233(5): 3846-3854, 2018. PMID: 28703277. DOI: 10.1002/jcp.26095
    OpenUrl
  33. ↵
    1. Kim YW,
    2. Kim EY,
    3. Jeon D,
    4. Liu JL,
    5. Kim HS,
    6. Choi JW,
    7. Ahn WS
    : Differential microrna expression signatures and cell type-specific association with taxol resistance in ovarian cancer cells. Drug Des Devel Ther 8: 293-314, 2014. PMID: 24591819. DOI: 10.2147/dddt.S51969
    OpenUrl
  34. ↵
    1. Oh CK,
    2. Lee SJ,
    3. Park SH,
    4. Moon Y
    : Acquisition of chemoresistance and other malignancy-related features of colorectal cancer cells are incremented by ribosome-inactivating stress. J Biol Chem 291(19): 10173-10183, 2016. PMID: 26961878. DOI: 10.1074/jbc.M115.696609
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (10)
Anticancer Research
Vol. 40, Issue 10
October 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function
CHANG-KYU OH, JEONG JUN PARK, MIHYANG HA, HYE JIN HEO, JUNHO KANG, EUN JUNG KWON, JI WAN KANG, YOUNGJOO KIM, JIN MO KANG, SEUNG ZHOO YOON, YEJI KO, DAI SIK KO, YUN HAK KIM
Anticancer Research Oct 2020, 40 (10) 5601-5609; DOI: 10.21873/anticanres.14573

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function
CHANG-KYU OH, JEONG JUN PARK, MIHYANG HA, HYE JIN HEO, JUNHO KANG, EUN JUNG KWON, JI WAN KANG, YOUNGJOO KIM, JIN MO KANG, SEUNG ZHOO YOON, YEJI KO, DAI SIK KO, YUN HAK KIM
Anticancer Research Oct 2020, 40 (10) 5601-5609; DOI: 10.21873/anticanres.14573
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma
  • Google Scholar

More in this TOC Section

  • Comprehensive Analysis of KREMEN2 as an Immunotherapeutic and Prognostic Biomarker in Pan-Cancer
  • PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
  • Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma
Show more Experimental Studies

Similar Articles

Keywords

  • Ovarian epithelial cancer
  • LRRC17
  • survival analysis
  • zebrafish
  • apoptosis
  • gene expression omnibus
  • TCGA
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire